Multiple Sclerosis Article

Cannabidiol to Improve Mobility in People with Multiple Sclerosis

Source: 
https://www.ncbi.nlm.nih.gov

Link: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874292/

Article Summary:
Multiple sclerosis (MS) affects around 2.3 million people globally, causing symptoms like pain, muscle spasticity, fatigue, inflammation, and depression, significantly impacting patients’ quality of life. Despite advances in disease-modifying therapies, these treatments don’t cure MS symptoms. Many MS patients seek alternative therapies like cannabis, which contains various cannabinoids, notably cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC). CBD, in particular, exhibits several beneficial effects, including anti-inflammatory, antioxidative, antiemetic, antipsychotic, and neuroprotective properties, with studies demonstrating its safety even at high doses and with chronic use. A substantial proportion of MS patients use cannabis to manage symptoms, finding relief from pain, spasticity, and fatigue. While there’s limited empirical data on cannabis’s direct impact on physical mobility, evidence suggests that CBD-enriched cannabis may reduce muscle spasticity, pain, and inflammation, potentially enhancing mobility. Cannabis has also been associated with decreased usage of prescription drugs, especially opioids, benzodiazepines, and antidepressants, commonly prescribed for MS-related symptoms. Despite objections related to limited scientific evidence, legal status, social stigma, dependency, and psychoactive effects, CBD’s safety profile and potential benefits warrant further investigation and consideration for managing MS symptoms. However, caution is advised regarding CBD-drug interactions, labeling accuracy of CBD extracts, and the possibility of testing positive for THC in urine drug tests when using CBD products. Overall, although more research is necessary, CBD-enriched cannabis may offer promise in improving the mobility of individuals with MS.